DK1140026T3 - Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme - Google Patents

Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme

Info

Publication number
DK1140026T3
DK1140026T3 DK99960556T DK99960556T DK1140026T3 DK 1140026 T3 DK1140026 T3 DK 1140026T3 DK 99960556 T DK99960556 T DK 99960556T DK 99960556 T DK99960556 T DK 99960556T DK 1140026 T3 DK1140026 T3 DK 1140026T3
Authority
DK
Denmark
Prior art keywords
preparing
same
receptor antagonist
biodegradable polymer
serotonin receptor
Prior art date
Application number
DK99960556T
Other languages
English (en)
Inventor
Rachel S Kohn
Stephen J Hanley
Stephen J Comiskey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1140026T3 publication Critical patent/DK1140026T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
DK99960556T 1998-12-16 1999-11-22 Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme DK1140026T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
DK1140026T3 true DK1140026T3 (da) 2006-01-02

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99960556T DK1140026T3 (da) 1998-12-16 1999-11-22 Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme

Country Status (35)

Country Link
EP (1) EP1140026B1 (da)
JP (1) JP4759141B2 (da)
KR (1) KR100707710B1 (da)
CN (1) CN1195497C (da)
AP (1) AP1769A (da)
AR (1) AR021652A1 (da)
AT (1) ATE303795T1 (da)
AU (1) AU770673B2 (da)
BG (1) BG65500B1 (da)
BR (1) BR9916276A (da)
CA (1) CA2355077C (da)
CR (1) CR6424A (da)
CZ (1) CZ301947B6 (da)
DE (1) DE69927177T2 (da)
DK (1) DK1140026T3 (da)
EA (1) EA004502B1 (da)
EE (1) EE200100314A (da)
ES (1) ES2245128T3 (da)
HK (1) HK1041645B (da)
HR (1) HRP20010446A2 (da)
HU (1) HU226586B1 (da)
ID (1) ID28909A (da)
IL (2) IL143761A0 (da)
ME (2) MEP19408A (da)
NO (1) NO20012981L (da)
NZ (1) NZ511962A (da)
OA (1) OA11728A (da)
PL (1) PL196822B1 (da)
RS (1) RS50123B (da)
SK (1) SK285812B6 (da)
TR (1) TR200101759T2 (da)
TW (1) TWI221418B (da)
UA (1) UA73101C2 (da)
WO (1) WO2000035423A1 (da)
ZA (1) ZA200104899B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
AU2002256694A1 (en) * 2001-03-20 2002-10-03 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
SK14182003A3 (sk) * 2001-05-23 2004-05-04 Hexal Ag Homogenizát pre implantáty a mikročastice
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
US11672755B2 (en) * 2019-12-31 2023-06-13 Wanka Tanka Ltd. Extended release plastic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CH679207A5 (da) * 1989-07-28 1992-01-15 Debiopharm Sa
DK0528978T3 (da) * 1990-05-16 2003-02-17 Southern Res Inst Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
KR100211713B1 (ko) * 1990-06-01 1999-08-02 슈테펜 엘. 네스비트 (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm

Also Published As

Publication number Publication date
KR20010082359A (ko) 2001-08-29
CR6424A (es) 2004-02-26
CZ20012157A3 (cs) 2001-09-12
BG65500B1 (bg) 2008-10-31
EP1140026B1 (en) 2005-09-07
PL348233A1 (en) 2002-05-20
YU41401A (sh) 2003-12-31
HUP0105048A3 (en) 2002-09-30
MEP19408A (en) 2010-06-10
AU770673B2 (en) 2004-02-26
AR021652A1 (es) 2002-07-31
EA200100551A1 (ru) 2001-10-22
HK1041645A1 (en) 2002-07-19
CN1330536A (zh) 2002-01-09
CA2355077C (en) 2009-05-26
ID28909A (id) 2001-07-12
PL196822B1 (pl) 2008-02-29
SK285812B6 (sk) 2007-08-02
RS50123B (sr) 2009-03-25
HK1041645B (zh) 2005-07-29
EE200100314A (et) 2002-08-15
NO20012981L (no) 2001-07-27
ATE303795T1 (de) 2005-09-15
WO2000035423A1 (en) 2000-06-22
DE69927177D1 (de) 2005-10-13
JP4759141B2 (ja) 2011-08-31
ES2245128T3 (es) 2005-12-16
TWI221418B (en) 2004-10-01
NZ511962A (en) 2003-06-30
EA004502B1 (ru) 2004-04-29
NO20012981D0 (no) 2001-06-15
JP2002532408A (ja) 2002-10-02
TR200101759T2 (tr) 2001-12-21
OA11728A (en) 2005-02-01
SK8282001A3 (en) 2001-11-06
HUP0105048A2 (hu) 2002-05-29
HRP20010446A2 (en) 2002-06-30
CZ301947B6 (cs) 2010-08-11
KR100707710B1 (ko) 2007-04-18
IL143761A (en) 2006-08-01
BR9916276A (pt) 2001-09-04
UA73101C2 (en) 2005-06-15
AP1769A (en) 2007-08-22
AU1742500A (en) 2000-07-03
DE69927177T2 (de) 2006-06-08
IL143761A0 (en) 2002-04-21
WO2000035423A9 (en) 2002-08-22
BG105591A (en) 2002-01-31
CN1195497C (zh) 2005-04-06
EP1140026A1 (en) 2001-10-10
AP2001002198A0 (en) 2001-09-30
CA2355077A1 (en) 2000-06-22
HU226586B1 (en) 2009-04-28
ME00066B (me) 2010-06-10
ZA200104899B (en) 2002-09-16

Similar Documents

Publication Publication Date Title
DK1140026T3 (da) Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme
CY2010003I2 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
NO20021633D0 (no) Kjöretöymontert plast-trommel for betongblanding og fremgangsmåter for fremstilling av samme
DE60042914D1 (de) Halbleitervorrichtung und verfahren zu ihrer herstellung
DE60023211D1 (de) Materialprüfung
FI20000154A7 (fi) Menetelmä tyhjätilojen täyttämiseksi raemaisella aineella
DE60026169D1 (de) Selektive neurokinin-antagonisten
DE60037977D1 (de) Hydrogenierte vinylaromatische polymerschaumstoffe
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE69917815D1 (de) Polymere zusammensetzung
DE60018844D1 (de) Hitzebeständiger Polymerschaumstoff
NO20015658L (no) Polymermaterialer
FI991088L (fi) Integriteetin suojausmenetelmä radioverkkosignalointia varten
NO20013997L (no) Reseptoranalyse
NO20004503D0 (no) Vitronectin-reseptor-antagonister
FI19992851L (fi) Palvelujen lähetys pakettiverkossa
DE69815835D1 (de) Schäumbare polymerzusammensetzung
NO20020644D0 (no) Nye integrinreseptor-antagonister
DE60018079D1 (de) Polymerzusammensetzung
DK1047666T3 (da) Nye fremgangsmåder til fremstilling af ketiminer
DK1146874T3 (da) Vitronectinreceptoragonist
NO983972D0 (no) Polymermateriale med lav densitet
DE69932426D1 (de) In der Schmelze verarbeitbares Polytetrafluorethylen
DK0943650T3 (da) Sammensætning på basis af ethylenpolymer, fremgangsmåde til fremstilling heraf og anvendelse heraf